Videos

Catamaran Corporation Senior Vice President of Pharmacy Operations and Industry Albert Thigpen discusses the impact from the high cost of specialty medications on overall drug spending in 2014.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.

Shannon Manzi, PharmD, EMT, describes the sort of training given to pharmacists who serve on disaster medical assistance teams.

Starlin Haydon-Greatting, MS, BSPharm, FAPHA, discusses the range of education and training that prepares pharmacists to play a role in patient-centered diabetes care.

Gary Rice, RPh, MS, MBA, vice president of clinical services at Diplomat Specialty Pharmacy, discusses how HIPAA laws could change the use of electronic adherence tools.

David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists, discusses changes in insurance reimbursement for compounded medications.

Shannon Manzi, PharmD, EMT, describes the experience of helping to respond to the Boston Marathon bombing in April 2013.

Suzanne Tschida, PharmD, BCPS, vice president of specialty benefit and outcomes strategy at OptumRx, talks about promoting patient adherence.

Suzanne Tschida, PharmD, BCPS, vice president of specialty benefit and outcomes strategy at OptumRx, talks about how specialty medications are better suited for distribution through a specialty pharmacy over a retail location.

Sara Anvari, MD, discusses the function of histamine in the immune response and treatment with antihistamines.

Leonard Bielory, MD, reviews challenging cases of ocular allergy and discusses treatment options.

Luz Fonacier, MD, talks about the diagnosis and management of atopic dermatitis.

Gary Rice, RPh, MS, MBA, vice president of clinical services at Diplomat Specialty Pharmacy, talks about Diplomat's adherence program.

Suzanne Tschida, PharmD, BCPS, vice president of specialty benefit and outcomes strategy at OptumRx, talks about how benefit design, financial assistance programs, and co-pay cards can help make medications affordable for patients.

Jonathan G. Marquess, PharmD, CDE, explains that employers can save a great deal on health care costs by helping their employees with diabetes effectively manage their condition.

Gary Rice, RPh, MS, MBA, vice president of clinical services at Diplomat Specialty Pharmacy, discusses compliance packaging options.

Jeff Fudin, PharmD, FCCP, argues that the way to make hydrocodone combination products safer for patients is to provide more education for those who prescribe the medications and pharmacists who dispense them.

Mary Lynn McPherson, PharmD, explains why hydrocodone combination products should no longer be categorized as Schedule III drugs.

Payers will encourage the use of biosimilars where appropriate through the use of step edits, lower tiers, and novel strategies, said Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.

Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II could lead to increased prescription of codeine, a much "sloppier" drug that could create problems for patients.

Mary Lynn McPherson, PharmD, argues that rescheduling hydrocodone combination products will lead to more responsible prescribing of the drugs and monitoring of their use.

Jeff Fudin, PharmD, FCCP, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.

Mary Lynn McPherson, PharmD, explains how rescheduling hydrocodone combination products as Schedule II drugs will help reduce levels of abuse.

Jeff Fudin, PharmD, FCCP, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.

Mary Lynn McPherson, PharmD, discusses why hydrocodone combination products were categorized as Schedule III in the first place.

Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.

Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.

Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.

University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

Martin R. Stämpfli, PhD, explains the development of COPD in his lecture at the seminar "COPD-Bridging the Gap between Science and Clinical Care."